Epigenetics
October 15, 2026
Arghavan Nepton, Sonya C. Faber, Zachary A. Kaminsky et al.
Ketamine produces rapid antidepressant effects, but the molecular processes associated with their persistence remain poorly defined in humans. We examined longitudinal DNA methylation changes in 10 adults with major depressive disorder undergoing ketamine-assisted psychotherapy using two pre-treatment assessments (T1, T2) and one post-treatment assessment (T3). Participants received three...
The oncologist
October 15, 2026
Keenan Wills Davis, Michelle C. Bach, JoEllen Schimmels et al.
Psychedelic-assisted therapy (PAT) is increasingly discussed as a potential intervention for anxiety, depression, and existential distress among patients with advanced cancer. Yet the ethical challenges of PAT for patients approaching the end of life remain underdeveloped, particularly for oncologists who may be asked to counsel patients or consider referral to clinical trials. This article...
Australasian Psychiatry
October 13, 2026
Adam Bayes, Colleen Loo
ObjectiveThe ideas presented in this paper are based on a presentation at a festschrift event marking the retirement of Professor Gordon Parker from UNSW, Sydney. Drawing on Gordon's depressive subtyping approach and his critiques of a unitary view of major depressive disorder and treatment-resistant depression (TRD), we aim to (i) explore differing models of ketamine for TRD - biomedical...
Cureus
October 12, 2026
Anirudh Bakam
Dissociative neurological symptom disorder (DNSD), termed functional neurological symptom disorder in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), presents with neurological symptoms not explained by structural disease.The first line treatment of DNSD is psychotherapy, but when the conflict maintaining the symptoms cannot be put into words,...
Routledge eBooks
October 9, 2026
Susan Cameron
Psychedelics have re-emerged in this century as a popular substance to use by people of different ages and socio-economic status. The reasons for use vary between recreational and treatment focused. The Controlled Substance Act of 1970, signed by then President Richard Nixon, created a ban on the use of these substances in the United States, but advocates have found reason to revisit the...
Therapeutic Advances in Psychopharmacology
October 8, 2026
Gianluca A. Florineth, Anna L. Boeker, Felix Müller et al.
Background Classic psychedelics show potential for treating psychiatric disorders, yet the psychological framework of psychedelic-assisted therapy (PAT) remains underspecified. As regulatory approval approaches, defining the contribution of psychological interventions to clinical outcomes is critical for both mechanism inference and implementation. Objectives To systematically review the...
OSF Preprints
October 7, 2026
Suzanne Grant, Maria González, Hannah Adler
preprint
The objective of this scoping review is to map the extent, range, and types of evidence related to psilocybin-assisted psychotherapy in people with cancer, including the types of psychotherapy used, models of delivering therapy, and associated outcomes, as reported in qualitative and quantitative studies.
ODU Digital Commons
October 6, 2026
Elif Bor
As public and scientific interest in psychedelic-assisted therapy (PAT) continues to grow, counselors are increasingly encountering clients who are exploring or engaging in psychedelic use for therapeutic purposes. Such encounters introduce new ethical, clinical, and professional considerations. Counselors must develop an informed understanding of psychedelics and their effects, recognize the...
Frontiers in Public Health
October 6, 2026
Vivian W. L. Tsang, Faizan Bhatia, Anne Ferrey et al.
Background: The group therapy model has been recently favored as a means of conducting psychedelic assisted therapies for mental health disorders. However, there is a paucity of literature showing strengths or drawbacks of this approach and comparisons of safety and efficacy to individual therapy. This systematic review aims to address this gap in literature. Methods: We included original...
Journal of Psychedelic Studies
October 5, 2026
Shannon Dames
Abstract: Background and aims: In Western clinical contexts, dissociation is a common transdiagnostic response to overwhelm and is highly relevant to integration capacity. In psychedelic-assisted therapy (PaT), non-ordinary states may open access to emotionally intense material while also activating protective distance when the experience outpaces coping capacity. This article introduces a...
Canadian family physician Medecin de famille canadien
October 2026
Daniel Shane, Sabrina Akhtar, Emma Hapke
To review psychedelic-assisted psychotherapy (PAP), including its principles, mechanisms of action, safety considerations, and current state of evidence relevant to Canadian primary care. The evidence of PAP is evolving and is primarily derived from phase 2 and 3 clinical trials in specialized research settings. Systematic reviews and meta-analyses suggest potential benefit for selected...
Journal of Affective Disorders Reports
October 1, 2026
Kevin Byrne, Madeleine Odette, Eric L Garland et al.
ABSTRACT Background Healthcare workers experienced amplified depression and burnout during COVID-19. Both Mindfulness Based Stress Reduction (MBSR) and psilocybin have been shown to reduce depressive symptoms in this population, however the psychological mechanisms by which adding psilocybin to mindfulness training improves depression and trait mindfulness remain incompletely characterized....
Frontiers in Psychiatry
September 21, 2026
Phil Wolfson, Cody Carroll
Introduction Ketamine Assisted Psychotherapy (KAP) is a developing modality with broad impact on humans suffering with a variety of emotional and relationship difficulties that encompass many diagnostic entities. Our application of KAP has extended to and included the treatment of adolescents and young adults in a family therapy format. Given the increasing scope and complexity of the...
npj Mental Health Research
September 16, 2026
Orly Lipsitz, Ryan M Brudner, Zoe Doyle et al.
Cluster B personality disorders (PDs) are highly comorbid with depression and are associated with attenuated antidepressant response. No clinical trials to date have reported on psilocybin-assisted psychotherapy (PAP) in comorbid treatment-resistant depression (TRD) and PDs. This is the first clinical trial to describe a subgroup of ten participants with a comorbid PD ( n = 9 cluster B; n = 1...
Applied Drug Research Clinical Trials and Regulatory Affairs
September 14, 2026
A S Shikha, Jignesh Shah, Darshil B. Shah et al.
Introduction: Psychedelic-assisted therapy has resurfaced as a promising intervention for treatment-resistant psychiatric disorders. However, regulatory pathways differ considerably across countries because of social, ethical, legal, and political factors. Methods: This review was conducted using the regulatory frameworks of Australia, Brazil, and the USA, along with publicly accessible data,...
OSF Preprints
September 10, 2026
Bartosz Helfer, Katarzyna Henke‐Ciążyńska, Daniel Pankowski et al.
preprint
The original data comprise the extraction, coding, identity mappings and appraisals produced for the accompanying meta-research study. Their source material is previously published literature.
The International Journal of Neuropsychopharmacology
September 9, 2026
Katarzyna Henke‐Ciążyńska, Daniel Pankowski, Bartosz Helfer
Abstract Background Systematic reviews with meta-analyses (SR-MAs) of psychedelic-assisted psychotherapy (PAP) guide clinical and policy decisions. Their trustworthiness depends, in part, on how consistently different SR-MAs assess risk of bias (RoB) in the same underlying randomized controlled trials (RCTs), and how transparently those judgments are justified. Aims & Objectives To summarise...
The International Journal of Neuropsychopharmacology
September 9, 2026
David Erritzøe
Abstract Background Recent clinical and neuroscientific work has revived interest in psychedelic-assisted therapies as promising treatments for a range of psychiatric conditions. Mechanistically, classical psychedelics and atypical agents such as ketamine appear to act as catalysts of neural and psychological flexibility, disrupting entrenched patterns of activity in “stuck” brain networks and...
Journal of Psychopharmacology
September 7, 2026
Torsten Passie, Michiel van Elk
Common wisdom in the psychedelic literature suggests that early controlled trials of psychedelic therapy were methodologically flawed. In this review we challenge this view and discuss 11 controlled studies that were conducted in the United States and Canada between 1965 and 1977 to evaluate psychedelic (peak) therapy for individuals suffering from alcohol and opioid use disorder and...
Current Addiction Reports
September 2, 2026
Kathryn Fletcher, Jack Freestone, Nadine Ezard et al.
Abstract Purpose of Review Psychedelic-assisted therapy (PAT) has re-emerged as a potential intervention for substance use disorders (SUDs), yet the psychological mechanisms underlying behaviour change remain poorly synthesised. This scoping review mapped and evaluated proposed psychological processes underpinning PAT in adults with SUDs. Recent Findings Peer-reviewed English-language empirical...